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A N U S C R I P T 3 BACKGROUND: Mycophenolate mofetil (MMF) is commonly prescribed after transplantation and has important advantages over other immunosuppressive drugs but frequent gastrointestinal (GI) side effects limit its use. The mechanism(s) underlying MMF-related GI toxicity have yet to be elucidated.
METHODS:
To investigate MMF-related GI toxicity, mice were fed chow containing MMF (0.563%) and multiple indices of toxicity, including weight loss and colonic inflammation, were measured. Changes in intestinal microbial composition were detected using 16S rRNA Illumina sequencing and downstream PICRUSt analysis was used to predict involved metagenomic pathways. Germ-free (GF) mice and mice treated with orally-administered broad-spectrum antibiotics (ABX) were utilized to interrogate the importance of the microbiota in MMF-induced GI toxicity.
RESULTS:
Mice treated with MMF exhibited significant weight loss, related to loss of body fat and muscle, and marked colonic inflammation. MMF exposure was associated with changes in gut microbial composition, demonstrated by a loss of overall diversity, expansion of Proteobacteria (specifically Escherichia/Shigella) and enrichment of genes involved in lipopolysaccharide (LPS) biosynthesis which paralleled increased levels of LPS in the feces and serum. MMF-related GI toxicity was dependent on the intestinal microbiota, as MMF did not induce weight loss or colonic inflammation in GF mice. Furthermore, ABX prevented and reversed MMF-induced weight loss and colonic inflammation.
CONCLUSIONS:
An intact intestinal microbiota is required to initiate and sustain the GI toxicity of MMF. MMF treatment causes dynamic changes in the composition of the intestinal microbiota that may be a targetable driver of the GI side-effects of MMF.
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Introduction
Following transplantation, potent immunosuppressive drugs (ISDs) are required to prevent recipient immune activation and allograft injury. Mycophenolate mofetil (MMF) is a prodrug whose active metabolite mycophenolic acid (MPA) inhibits inosine monophosphate dehydrogenase and suppresses the proliferation of T and B lymphocytes (1) . MMF is the antiproliferative agent of choice in combination with a calcineurin inhibitor for maintenance immunosuppression post-heart and lung transplantation (2) . However, despite the proven advantages of MMF therapy, frequent gastrointestinal (GI) side effects limit its use and tolerability. MMF toxicity affects 45% of patients and ranges in severity from nausea, vomiting, diarrhea and abdominal pain to weight loss and colitis resembling inflammatory bowel disease (3, 4) (5) (6). MMF-related GI toxicity can lead to dosage reduction or discontinuation, which has been associated with rejection and allograft loss (7) (8) (9) .
While the mechanism(s) contributing to MMF-related GI toxicity have yet to be well characterized, we recently reported a clinical case wherein shifts in the intestinal microbiota were associated with the onset of GI side-effects (10) . The gut microbiota, referring to all of the microorganisms in this niche, and its associated metagenome (microbiome) influences diverse aspects of host physiology and changes in its composition impacts host health (11, 12) . The stability of the microbiota is associated with positive health outcomes, while disruption has been linked to disease (13, 14) . Medications, including ISDs, can alter the gut microbiota (15, 16 ) and even trigger intestinal dysfunction and inflammation (17) (18) (19) . Changes in the microbiota following solid organ transplantation (SOT) have been reported (10, (20) (21) (22) , but the influence of ISDs on the microbiome remains understudied. In the present study, we interrogated the effect of MMF exposure on the gut microbiome and investigated the role the microbiota plays in MMFinduced GI toxicity in mice.
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Methods
Animal studies
Specific pathogen-free (SPF) male C57BL/6, B6.129S7-Rag1<tm1Mom>/J (Rag1-/-) and BALB/c mice between 7 and 10 weeks of age (Jackson Laboratories) were housed in SPF conditions in sterilized, filter-top cages. Littermates were used throughout all studies to control for differences in the composition of the intestinal microbiota. Germ-free (GF) C57BL/6 mice were generated by two-stage embryo transfer, as previously described (23) mins dry) to ensure sterility. To deplete the intestinal microbiome, mice were exposed to ampicillin (1 g/L), metronidizole (1 g/L), neomycin (1 g/L) and vancomycin (500 mg/L) combined in the drinking water for two weeks (25). Body composition was measured by quantitative nuclear magnetic resonance using a Minispec LF-110 NMR Analyzer (Bruker Optics, Milton, ON, Canada). MPA and mycophenolic acid glucuronide (MPAG) were measured using ultrahigh performance liquid chromotography and mass spectrometry (LCMS; a full explanation of methods can be found in the supplementary materials online at jhltonline.org).
Detection of colonic inflammation
Myeloperoxidase (MPO) activity was measured in colonic tissue homogenates, as previously described (26) . Cytokine levels were assessed in colonic homogenates and serum using the Mouse Cytokine/Chemokine 31-Plex Discovery Assay (Eve Technologies). Intestinal permeability was assessed by detection of lipopolysaccharide (LPS) in serum using the E.
TOXATE
TM kit (Sigma-Aldrich). LPS was also quantified in feces using human embryonic kidney (HEK)-Blue-mTLR4 cells (Invivogen), as previously described (27) . Procedures for isolation of lamina propria cells, flow cytometry and antibody clones used are found in the supplementary materials online at jhltonline.org.
Bacterial DNA isolation, Illumina sequencing and bioinformatics
Procedures for bacterial DNA isolation, Illumina sequencing, operational taxonomic unit 
Statistics
Statistical analyses were performed on data expressed as mean ± SEM, where n is the biological replicate (number of mice per group). Data were analyzed using either Student's ttest, one-way ANOVA with appropriate post hoc analysis, or two-way ANOVA. Analyses were performed using GraphPad Prism 7; in all cases, P <0.05 was considered significant.
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Results
MMF exposure causes rapid weight loss and macroscopic changes in the colon
To characterize the GI-related effects of MMF treatment, we examined multiple parameters after administering MMF to mice. Oral administration of MMF over the course of 8 days led to rapid and significant weight loss (loss of ~25% of body weight by day 8; 76.2 ± 0.5% of initial weight) when compared to control mice (Fig. 1A) . After withdrawing MMF, mice began to regain lost weight, but never fully recovered to the weight of control mice. These changes
were not the result of decreased food or water intake, as chow ( Fig. S1A ) and water consumption were not significantly different between groups. Significant decreases in fat mass and lean muscle mass, but not free fluid mass, were also observed in MMF-exposed mice ( 
MMF exposure causes colonic inflammation
In comparison to control animals, MMF-treated mice had significantly higher levels of intestinal granulocyte infiltration as measured by MPO activity ( 2C&D ), but no change in the number of eosinophils (Fig. S2B&C) . Evidence of increased inflammation occurred in the absence of gross microscopic mucosal damage (Fig. S3 ).
Intestinal toxicity of MMF occurs independently of adaptive immune cells and mouse strain
MMF is thought to selectively target B and T cells to suppress allograft-targeted immune responses (1). To determine whether the MMF-related GI toxicity was due to an effect on these cell populations, we performed experiments in Rag1 -/-mice (which lack mature B and T cells).
We found that Rag1 -/-mice displayed similar weight loss to wild type animals when treated with MMF ( Fig. 3A) . MMF-treated Rag1-/-mice also exhibited colon shortening (Fig. 3B ), decreased cecum weight (Fig. 3C ), decreased spleen weight (Fig. 3D ) and reduced hematocrit (Fig. 3F ).
The physiological and inflammatory changes induced by MMF were not strain-specific as BALB/c mice displayed similar changes as C57BL/6 mice when exposed to MMF for 8 days (Fig. S4 ).
MMF exposure causes changes in the diversity and composition of the fecal microbiota
Given that MMF toxicity occurred independently of lymphocytes and mouse strain, we hypothesized that the toxicity of MMF may be influenced by the intestinal microbiota. We first examined microbiota composition profiles in DNA extracted from fecal pellets collected every four days from mice fed control or MMF-containing chow (8 days on MMF then recovery for an additional 8 days following MMF withdrawal). As both control and MMF-exposed mice were switched to new diets at the beginning of the experiment, comparisons were performed at each time point, to ensure the control diet alone was not inducing large changes. Observed diversity (an α-diversity measure that counts the number of unique OTUs in each sample to determine
richness) measurements revealed that MMF treatment led to a rapid decrease in microbiota richness, as early as 4 days after drug exposure (Fig. 4A) . There was also a significant reduction in observed diversity on day 8 during MMF treatment, an effect that continued even after withdrawal of MMF. Control samples remained unchanged for the entire 16-day experiment (Fig. 4A) . The Shannon diversity measure of evenness, an estimate of both the richness and the relative abundance or distribution of all OTUs within a sample, did not uncover remarkable differences in the microbiota between control and MMF-treated mice, although there was decreased Shannon diversity in the experimental group at day 16 (Fig. 4A) .
Changes in the microbiota were further characterized by examining the distribution of bacterial phyla in each fecal sample. Figure Bacteroidetes continued to diminish (<5%). By day 16, Proteobacteria were still present and there was a clear expansion of Actinobacteria (Fig. 4B) .
The Bray-Curtis dissimilarity metric was used to compare the microbial diversity between groups over the time course of the experiment. Before administration of MMF-containing chow, all mice showed similar microbial profiles with overlapping clustering (Fig. 4C) . After 4 days of
MMF administration, the treated group had shifted away from the control group and, by day 8, the two groups were distinctly separate (Fig. 4C ). After withdrawal of MMF, the separation of the groups began to reverse with the MMF-treated group shifting back towards the control group, with no distinct clustering noticeable by day 16. We then examined the abundance of specific bacterial families over the course of MMF administration and its withdrawal. At the family level, we found that changes induced by MMF were widespread with several different patterns of change including both the depletion and enrichment of important intestinal bacterial populations (Fig. S5) .
MMF alters the microbiome, increasing the pathogenic potential of the intestinal microbiota
Examination within the Proteobacteria phylum on day 8 following MMF exposure revealed that this phylum was dominated by the genus Escherichia/Shigella (Fig. 5A) . Tracking of Escherichia/Shigella (the two of which cannot be resolved using 16S sequencing) over the course of MMF exposure showed that a gradual increase in this genus was associated with weight loss and other symptoms induced by MMF (Fig. 5B) . PICRUSt analysis identified an enrichment of genes encoding for enzymes involved in LPS biosynthesis, as identified from the Kyoto Encyclopedia of Genes and Genomes (KEGG) reference pathways (Fig. S6) , in the feces of mice after 8 days of MMF exposure (Fig. 5C ). These changes were associated with increased bioactive LPS detected in the feces (Fig. 5D ) and serum ( Fig. 5E ) of MMF-treated mice. Along with these changes we also observed a significant loss of the genera Akkermansia, Parabacteroides and Clostridium on day 8 following MMF exposure (Fig. 5F ).
MMF GI toxicity requires the presence of a microbiota
To determine whether the MMF-related GI toxicity was dependent on an intact intestinal microbiota, we performed experiments using GF mice. Before initiating the GF experiments, we ACCEPTED MANUSCRIPT
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confirmed that autoclaved MMF-containing chow maintained its toxicity (Fig. S7) . When fed to GF mice, MMF-supplemented chow did not trigger weight loss, nor did it induce colon shortening. Furthermore, MMF-treated GF mice exhibited the same cecum weight and spleen weight as GF mice fed the control diet ( Fig.6A-E) . Hematocrit and MPO levels were slightly lower in MMF-fed GF mice (Fig. 6F,G) but, in the absence of the gut microbiota, the overt GI toxicity of MMF, including colonic inflammation, like that seen in SPF mice, was not observed.
Antibiotics prevent and reverse the toxicity induced by MMF
To test whether targeting the microbiota could prevent the effects of MMF, intestinal bacteria were depleted using a cocktail of broad-spectrum antibiotics (25) for two weeks prior to the administration of MMF-containing chow. Early antibiotic administration was protective, with ABX-treated mice showing no significant decreases in weight, colon length, spleen weight, or hematocrit ( Fig. 7A-C) . Pretreatment with ABX also prevented the loss of body fat and lean mass (Fig. 7D) . ABX administration did not significantly change serum levels of MPA, MPAG (Fig. 7E ) or liver expression of drug transporters involved in the metabolism of MMF (Fig S8) .
Pretreatment with ABX also prevented colonic inflammation (Fig. 7F ) and inflammatory mediator release in the serum and colon (Fig. S9) . Taking an interventional approach, we next assessed whether ABX could treat/reverse established MMF-related GI toxicity. Interestingly, after 8 days of MMF exposure, ABX treatment was sufficient to promote significant increases in body weight, colon length, and cecum weight, during continued MMF administration (Fig. S10) .
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Conclusions
The reported frequency of MMF-related GI side effects ranges between 12-80% (8, 31-34) with 22% requiring dose reduction or discontinuation of the drug (8) . With evidence that MMF impacts the gut microbiota (10, 35), we developed a model to study the effects of MMF on the intestinal microbiota and its associated microbiome. In two wild type strains (C57BL/6 and BALB/c), and in Rag1-deficient mice, we have shown that MMF treatment leads to rapid and significant weight loss accompanied by gross colonic changes and inflammation, recapitulating the effects seen in humans (36, 37). We also observed that MMF administration prompted alterations in the composition of the microbiota and its associated metagenome. The presence of the microbiota appears to be a critical factor necessary for the toxicity of MMF, as weight loss and colonic pathology were absent in GF mice, and the administration of antibiotics was sufficient to both prevent and reverse the phenotype associated with MMF exposure.
Alterations in the intestinal microbiota have been reported after SOT and hematopoietic stem cell transplantation (HSCT) in both mice and humans, with decreased bacterial diversity being a common finding (21, 38-41). In our mice, we noted a decrease in observed diversity, but we did not see an early change in Shannon Diversity related to MMF treatment. These findings are consistent with a human study showing no change in the Shannon diversity of the intestinal microbiota within the first month after kidney transplantation while patients were maintained on ISDs (42) . In addition to changes in diversity, the depletion or enrichment of certain bacteria following transplantation has been reported, with an increase in Lactobacillales and a decrease in Clostridiales in humans and mice undergoing HSCT (39) . An increase in Proteobacteria, accompanied by decreases in Bacteroides, Ruminococcus, Coprococcus and Dorea, was seen in kidney transplant patients with diarrhea, but, given the multiple confounders, it could not be 
